Research Topics
| Mahesh N SamtaniSummaryAffiliation: Johnson and Johnson Pharmaceutical Research and Development Country: USA Publications
| Collaborators
|
Detail Information
Publications
Simple pharmacometric tools for oral anti-diabetic drug development: competitive landscape for oral non-insulin therapies in type 2 diabetesMahesh N Samtani
Clinical Pharmacology Advanced PK PD Modeling and Simulation, Johnson and Johnson Pharmaceutical Research and Development, Raritan, New Jersey 08869, USA
Biopharm Drug Dispos 31:162-77. 2010..8% or more and possess safety profiles similar to newer anti-diabetic agents. Thus, this study proposes a suite of simple yet powerful tools to guide type-2-diabetes drug development...
Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypesMahesh N Samtani
Johnson and Johnson Pharmaceutical Research and Development, Clinical Pharmacology Department, Raritan, New Jersey 08869, USA
Br J Clin Pharmacol 75:146-61. 2013....- An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiativeMahesh N Samtani
Johnson and Johnson Pharmaceutical Research and Development, Raritan, NJ, USA
J Clin Pharmacol 52:629-44. 2012.... - Pharmacokinetic and pharmacodynamic modeling of pegylated thrombopoietin mimetic peptide (PEG-TPOm) after single intravenous dose administration in healthy subjectsMahesh N Samtani
Clinical Pharmacology, Advanced PK PD Modeling and Simulation, Johnson and Johnson Pharmaceutical R and D, 920 Route 202, PRD 2723, Raritan, NJ 08869, USA
J Clin Pharmacol 49:336-50. 2009.... - Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial dataMahesh N Samtani
Johnson Johnson Pharmaceutical Research Development, L L C, Raritan, NJ, USA
CNS Drugs 25:829-45. 2011..Population PK modelling presented in this review has helped provide practical guidance for administering this novel LAI antipsychotic... - Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychoticMahesh N Samtani
Clinical Pharmacology, Advanced PK PD Modeling and Simulation, Johnson and Johnson Pharmaceutical Research and Development, LLC, 920 Route 202, PRD 2723, Raritan, NJ 08869, USA
Clin Pharmacokinet 48:585-600. 2009..To characterize the population pharmacokinetics of paliperidone after intramuscular administration of its long-acting palmitate ester at various doses and at two different injection sites (deltoid and gluteal muscle)... - A novel subject synchronization clinical trial design for Alzheimer's diseaseTimothy Schultz
Janssen Pharmaceutical Companies of Johnson and Johnson, Raritan, NJ 08869, USA
J Alzheimers Dis 31:507-16. 2012.... - The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trialsNandini Raghavan
Janssen Pharmaceutical Companies of Johnson and Johnson, Raritan, NJ, USA
Alzheimers Dement 9:S21-31. 2013..A wealth of data exists in ADAS-Cog from both historical trials and contemporary longitudinal natural history studies that can provide insights about parts of the scale that may be better suited for MCI and early AD trials... - A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophreniaDanielle Coppola
Janssen Research and Development, LLC, Raritan, New Jersey, USA
BMC Psychiatry 12:26. 2012..This study evaluates safety and tolerability, as well as pharmacokinetics, of the highest marketed dose of PP (150 mg eq. [234 mg]) in stable patients with schizophrenia over a 1-year period... - Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patientsMahesh N Samtani
Clinical Pharmacology, Advanced PK PD Modeling and Simulation, Johnson and Johnson Pharmaceutical Research and Development, LLC, Titusville, NJ 08560, USA
Antimicrob Agents Chemother 54:2360-4. 2010..Results of pharmacokinetics/pharmacodynamics (PK/PD) modeling can guide dose optimization, thereby potentially increasing the clinical efficacy of doripenem against serious Gram-negative bacterial infections... - Pharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infectionsHolly Kimko
Johnson and Johnson Pharmaceutical Research and Development, LLC, 920 Route 202 South, Raritan, NJ 08869, USA
Antimicrob Agents Chemother 53:3371-4. 2009..A ceftobiprole regimen of 500 mg every 8 h as a 2-h infusion has a high probability of achieving a target of >or=30 or >or=50% T>MIC for patients with cSSSI due to gram-positive and gram-negative pathogens... - Management of antipsychotic treatment discontinuation and interruptions using model-based simulationsMahesh N Samtani
Janssen Research and Development, Raritan, NJ, USA
Clin Pharmacol 4:25-40. 2012..These pharmacokinetic model-based simulations analyze predicted antipsychotic plasma concentrations in nonadherence and treatment interruption scenarios and with treatment reinitiation... - Doripenem dosing recommendations for critically ill patients receiving continuous renal replacement therapyMahesh N Samtani
Clinical Pharmacology, Janssen Research and Development, L L C, 920 Route 202, Raritan, NJ 08869, USA
ISRN Pharmacol 2012:782656. 2012..This work was conducted to fulfill a health authority request and resulted in the addition of dosing recommendations to the Doribax Summary of Product Characteristics... - Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patientsPartha Nandy
Clinical Pharmacology, Advanced PK PD Modeling and Simulation, Johnson and Johnson Pharmaceutical Research and Development, LLC, Titusville, NJ 08560, USA
Antimicrob Agents Chemother 54:2354-9. 2010....